^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Gastric Cancer
    Drug:Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

    Excerpt:
    ......
    Trial ID:
    NCT07474324
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Clinical studies on the efficacy and safety of RC148 injection monotherapy and combination regimens in patients with locally advanced unresectable or metastatic malignant solid tumors.

    Excerpt:
    ......
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

    Excerpt:
    ...- HER2-expressing status determined by laboratory to be IHC 1+, 2+ or 3+....
    Trial ID:
    NCT05980481
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

    Excerpt:
    ...Use pre-treatment endoscopic biopsy samples for HER2 detection in the local laboratory: HER2 high expression confirmed after IHC results (defined as: IHC 2+ 3+); 7....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    This study aims to evaluate the efficacy and safety of Disitamab Vedotin combined with Cisplatin and Candelinib in the treatment of patients with locally advanced cervical cancer.

    Excerpt:
    ......
    Trial ID:
    ChiCTR2500114983
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Pharmacol
    Title:

    From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression

    Published date:
    01/05/2022
    Excerpt:
    The preliminary results show that RC48-ADC has satisfactory efficacy in HER2-positive or HER2-moderate expressed GC patients, and the adverse effects are tolerable. In addition, RC48-ADC has also shown promising antitumor effects in HER2-positive patients who have progressed after receiving anti-HER2 therapy....In conclusion, RC48-ADC exerted promising antitumor activity in HER2-positive as well as score of 2+ in IHC and ISH-negative AGC patients after progression of systematic treatment.
    DOI:
    10.3389/fphar.2021.757994